Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Anemia drugs
Pharma
Bristol Myers' clinical woes deepen with failed Reblozyl ph. 3
With the Reblozyl flop, all four of the pivotal trials that have read out this year for BMS’ currently marketed drugs have turned up negative.
Angus Liu
Jul 18, 2025 11:28am
Akebia unveils IRA-driven high price for Vafseo
Jul 11, 2024 10:54am
AstraZeneca finally drops roxadustat US rights
Feb 27, 2024 11:28am
BMS' Reblozyl, chasing $4B sales target, wins key FDA expansion
Aug 29, 2023 11:23am
GSK scraps plan to launch oral anemia drug beyond US, Japan
Jul 26, 2023 10:21am
ASCO: BMS' $4B plan for Reblozyl takes shape—with one caveat
May 25, 2023 5:00pm
